42.60
price down icon8.99%   -4.21
pre-market  Pre-market:  42.59   -0.010   -0.02%
loading

Tectonic Therapeutic Inc Stock (TECX) Latest News

pulisher
Feb 06, 2025

Petri Dish: VC firm's new $340M seed fund; Watertown biotech raises $185M - The Business Journals

Feb 06, 2025
pulisher
Feb 06, 2025

Brokerages Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $80.50 - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

Tectonic announces ~$185M capital raise - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Tectonic Therapeutic (NASDAQ:TECX) Shares Down 3.2%Here's Why - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data (NASDAQ:TECX) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

Tectonic secures $185 million in private equity funding - MSN

Feb 05, 2025
pulisher
Feb 04, 2025

Tectonic Therapeutic (NASDAQ:TECX) Given New $112.00 Price Target at Wells Fargo & Company - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

TECX (Tectonic Therapeutic Inc) may reap gains as insiders became active recently - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Tectonic Therapeutic (NASDAQ:TECX) Trading 6.7% Higher After Analyst Upgrade - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic (NASDAQ:TECX) Reaches New 52-Week HighTime to Buy? - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic to Raise $185 Million Via Private Investment in Public Equity Financing - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic Secures $185 Million in PIPE Deal - TipRanks

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic announces $185M private placement - TipRanks

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic (NASDAQ:TECX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Announces $185 Million Private Placement - The Bakersfield Californian

Feb 03, 2025
pulisher
Feb 03, 2025

Major Funding Alert: Tectonic Therapeutic Lands $185M from Elite Investors at Premium Price - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Tectonic Therapeutic (NASDAQ:TECX) Price Target Raised to $112.00 - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45 - TipRanks

Feb 02, 2025
pulisher
Feb 02, 2025

Tectonic Therapeutic (NASDAQ:TECX) Trading Down 13.3%Should You Sell? - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

Tectonic Therapeutic (NASDAQ:TECX) Stock Price Down 13.3%Here's What Happened - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Tectonic Therapeutic (NASDAQ:TECX) Shares Up 6.7% on Analyst Upgrade - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Tectonic jumps on positive data from early-stage trial for lead asset - MSN

Jan 31, 2025
pulisher
Jan 30, 2025

Wall Street Rally: Dow Hits One-Month High as IBM Surges, Microsoft Declines – Market - HPBL

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic’s Plates Shift On Positive Phase Ib PH-HFpEF Data - News & Insights

Jan 30, 2025
pulisher
Jan 30, 2025

Wall Street relaxin as Tectonic plates up phase Ib heart data - BioWorld Online

Jan 30, 2025
pulisher
Jan 30, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic: Stock Spikes On Heart Failure Data — Why I See Further Upside (TECX) - Seeking Alpha

Jan 30, 2025
pulisher
Jan 30, 2025

Stock market news: Foxx Development Holdings +220.76%, Tectonic Therapeutic +117.03% among top gainers during mid day trading - Business Upturn

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data - MarketWatch

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic (TECX) Stock Soars On Positive Clinical Trial Update - Stocks Telegraph

Jan 30, 2025
pulisher
Jan 30, 2025

Stock market today: Foxx Development Holdings +243.94%, Alpha Modus Holdings +142.21% among top gainers in early trading - Business Upturn

Jan 30, 2025
pulisher
Jan 30, 2025

Dow Jumps Over 100 Points; Tesla Earnings Miss Views - Benzinga

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic Shares Soar Pre-Bell Following Interim Data From TX45 Trial -January 30, 2025 at 09:20 am EST - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic stock jumps on trial data for TX45 (TECX:NASDAQ) - Seeking Alpha

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic stock soars on positive trial data By Investing.com - Investing.com Canada

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic stock soars on positive trial data - Investing.com

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic Reports Positive Interim Results for TX45 - TipRanks

Jan 30, 2025
pulisher
Jan 30, 2025

Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Game-Changing Results: This New Drug Could Transform Pulmonary Hypertension Treatment - StockTitan

Jan 30, 2025
pulisher
Jan 28, 2025

Eli Lilly trial update on kidney drug hurts Tectonic - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Tectonic stock plunges on Eli Lilly trial update (TECX:NASDAQ) - Seeking Alpha

Jan 28, 2025
pulisher
Jan 28, 2025

Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success - TipRanks

Jan 28, 2025
pulisher
Jan 25, 2025

Tectonic Therapeutic (NASDAQ:TECX) Shares Up 8.2%Here's What Happened - MarketBeat

Jan 25, 2025
pulisher
Jan 20, 2025

Clarius Group LLC Invests $468,000 in Tectonic Therapeutic (NASDAQ:TECX) - MarketBeat

Jan 20, 2025
pulisher
Jan 13, 2025

Tectonic Therapeutic Highlights Pipeline and Financial Strength - TipRanks

Jan 13, 2025
pulisher
Jan 12, 2025

Brokerages Set Tectonic Therapeutic (NASDAQ:TECX) Price Target at $72.25 - Defense World

Jan 12, 2025
pulisher
Jan 10, 2025

Tectonic Therapeutic (NASDAQ:TECX) Shares Down 8.8%Should You Sell? - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth - Simply Wall St

Jan 10, 2025
pulisher
Jan 09, 2025

AVROBIO, Inc. Announces Acceptance of Investigational New Drug Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis - Marketscreener.com

Jan 09, 2025
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Cap:     |  Volume (24h):